^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | HRS8807 (Selective estrogen receptor covalent antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
686P - Phase I study of HRS8807, an oral selective ER covalent antagonist (SERCA), in ER+/HER2- locally advanced (LA) or metastatic (M) breast cancer (BC)
Published date:
10/16/2023
Excerpt:
3 pts achieved PR (1 at 75 mg and 2 at 150 mg; in which 2 had prior SERD [fulvestrant] and all had prior CDK4/6i in the M setting; treatment duration was 8.4, 8.6+, and 7.0+ mo). Impressively, ORR reached 42.9% (95% CI 9.9-81.6) in overall population, and 66.6% (95% CI 9.4-99.2) at 150 mg and 33.3% (95% CI 0.8-90.6) at 75 mg....HRS8807 was well-tolerated and showed early signs of robust antitumor activity, favorable PK properties (both parent and active metabolite), and high ER occupancy in pretreated ER+/HER2- LA/M BC.
Trial ID: